Form 4: Mirum CEO Peetz Reports RSU Vesting and Tax-Related Stock Sale

Mirum Pharmaceuticals CEO Christopher Peetz reported the vesting of 12,797 restricted stock units and a subsequent sale of 7,098 shares to cover tax obligations.

Summary

• Christopher Peetz, Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc. (MIRM), reported transactions related to his beneficial ownership.
• On January 21, 2026, 12,797 restricted stock units (RSUs) vested, converting into an equal number of common stock shares.
• Following the RSU vesting, Peetz directly owned 170,831 shares of common stock.
• On January 22, 2026, Peetz disposed of 7,098 shares of common stock at a price of $93.3252 per share.
• This sale was conducted to cover tax withholding obligations associated with the RSU vesting.
• After these transactions, Peetz directly owns 163,733 shares of common stock.
• Additionally, Peetz indirectly owns 187,500 shares of common stock through The Peetz Family Trust.
• A total of 25,593 derivative securities (Restricted Stock Units) remain beneficially owned directly by Peetz following the reported transactions.
• The RSUs vest in three equal annual installments, with 1/3rd vesting on each anniversary of January 21, 2025, the Vesting Commencement Date.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation (RSU vesting and tax-related sale). It does not contain information that would significantly alter the investment thesis or indicate a strong positive or negative sentiment towards the company's performance or outlook.

Positives

• The vesting of restricted stock units aligns management's long-term interests with those of shareholders, as a portion of compensation is tied to future company performance.

Negatives

• The sale of 7,098 shares, even for tax purposes, reduces the direct ownership stake of the Chief Executive Officer in the company.

Future Outlook

The remaining 25,593 restricted stock units held by Christopher Peetz are scheduled to vest in annual installments, with the entire award vesting on the three-year anniversary of January 21, 2025.

Industry Context

Insider transactions, particularly those involving the vesting of restricted stock units and subsequent tax-related sales, are common occurrences in publicly traded companies across all industries, including the biotechnology and pharmaceutical sectors. These events are part of standard executive compensation packages designed to align management incentives with shareholder value over time.

Next Steps

• Future vesting of the remaining 25,593 restricted stock units on the anniversaries of January 21, 2025, until the three-year anniversary.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such events are common for executive compensation and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, CEO, Director, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, stock sale, tax withholding